All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Autoimmune hepatitis (AIH) is a very rare chronic progressive liver disease with autoimmune features \[[@pone.0187325.ref001],[@pone.0187325.ref002],[@pone.0187325.ref003]\]. Type 1 AIH is characterized by the presence of serum anti-nuclear antibodies (ANA) or anti-smooth muscle antibodies (ASMA) and type 2 AIH by type 1 liver-kidney microsomal antibodies. AIH is composed predominantly of type 1 in Japanese populations. Although the disease etiology is uncertain, it is considered that the genetic and environmental factors are associated with the pathogenesis of AIH. Many studies including a recent genome-wide association study \[[@pone.0187325.ref004]\] showed the genetic association of AIH with genes located within human leukocyte antigen (*HLA*) region. *HLA*-*DRB1\*03*:*01* and *\*04*:*01* are associated with AIH in European populations \[[@pone.0187325.ref005]\]; *\*04*:*05* is associated in Japanese and Korean populations \[[@pone.0187325.ref006],[@pone.0187325.ref007],[@pone.0187325.ref008],[@pone.0187325.ref009]\]. In addition, several studies have shown that *DRB1\*04*:*04*, *\*04*:*05*, and *\*13*:*01* are associated with AIH in Latin America \[[@pone.0187325.ref010],[@pone.0187325.ref011],[@pone.0187325.ref012],[@pone.0187325.ref013]\]. *DRB1\*08* alleles are also reported to be associated with AIH in Indian and Iranian, but not in Pakistani populations \[[@pone.0187325.ref014],[@pone.0187325.ref015],[@pone.0187325.ref016]\]. On the other hands, *DRB1\*15*:*01* is protective for the susceptibility of AIH in European and Japanese populations \[[@pone.0187325.ref005],[@pone.0187325.ref006]\]. *DRB1\*13*:*02*, which differ by one amino acid residue from *DRB1\*13*:*01*, is protectively associated with AIH in Latin America \[[@pone.0187325.ref011],[@pone.0187325.ref013],[@pone.0187325.ref017]\] and in Japan \[[@pone.0187325.ref008]\].

It was reported in the genome-wide association study that *HLA* is the sole strong genetic factor for the susceptibility of type 1 AIH \[[@pone.0187325.ref004]\]. The *HLA* region was scanned and the most important loci for the susceptibility of type 1 AIH was reported to be *DRB1* \[[@pone.0187325.ref018]\]. It was suggested that no other genes in the *HLA* region are associated with type 1 AIH. However, *DRB1* is in strong linkage disequilibrium with *DQB1* and it is difficult to differentiate the role of *DRB1* and *DQB1* in the pathogenesis of type 1 AIH. Although *HLA* alleles are known to confer the risk for various autoimmune diseases, the precise mechanisms have not sufficiently been revealed. The risk alleles are different in these autoimmune diseases \[[@pone.0187325.ref019]\]. It was considered that different auto-antigens are presented by different disease-specific risk alleles; the presented auto-antigens are restricted by *HLA* alleles and are influenced by non-*HLA* genes, environmental factors, or precipitating events. The complex of auto-antigens and risk alleles stimulate self-reactive T cells, resulting in the eliciting of diseases \[[@pone.0187325.ref020]\]. In this study, we conducted an *HLA* association study in order to search *HLA* alleles or haplotypes predisposing or protective for Japanese AIH.

Materials and methods {#sec006}
=====================

Patients and healthy controls {#sec007}
-----------------------------

Three hundred sixty type 1 AIH patients were enrolled from the register of Japanese National Hospital Organization Liver Registry \[[@pone.0187325.ref021]\]. The AIH patients without any other types of liver diseases satisfied the criteria of International Autoimmune Hepatitis Group (IAIHG) for diagnosis of type I AIH \[[@pone.0187325.ref022]\]. The healthy controls (n = 1026; mean age ± SD, 37.7 ± 11.7 years, 303 male \[29.8%\]) were recruited at Sagamihara Hospital, the University of Tokyo, Teikyo University, and Kanazawa University \[[@pone.0187325.ref023],[@pone.0187325.ref024]\] or by the Pharma SNP Consortium (Tokyo, Japan) \[[@pone.0187325.ref025]\]. All the patients and the healthy individuals were native Japanese living in Japan. The study was reviewed and approved by University of Tsukuba Research Ethics Committee, Nagasaki University Research Ethics Committee, and the NHO central Institutional Review Board. Informed consents in writing were obtained from all the participants. The study was performed in accordance with the principles expressed in the Declaration of Helsinki.

Genotyping methods {#sec008}
------------------

Genotyping of *HLA-DRB1* and *DQB1* was conducted by the polymerase chain reaction with sequence-specific oligonucleotide probes (WAKFlow HLA typing kits, Wakunaga, Hiroshima, Japan), using the Bio-Plex 200 system (Bio-Rad, Hercules, CA). HLA-DR4 serological group includes *DRB1\*04*:*01*, *\*04*:*03*, *\*04*:*04*, *\*04*:*05*, *\*04*:*06*, *\*04*:*07*, and *\*04*:*10*. DR6 is composed of *DRB1\*13*:*01*, *\*13*:*02*, *\*14*:*03*, *\*14*:*04*, *\*14*:*05*, *\*14*:*06*, *\*14*:*07*, *\*14*:*29*, and *\*14*:*54*. DR8 consists of *DRB1\*08*:*02*, *\*08*:*03*, and *\*08*:*09*. Genotyping results of *HLA-DRB1* and *DQB1* for some of the AIH patients were previously reported \[[@pone.0187325.ref008]\]. Genotyping results of *DRB1* for all of the healthy controls (n = 1026) were previously reported \[[@pone.0187325.ref008],[@pone.0187325.ref023],[@pone.0187325.ref024]\]. Reported genotyping results of *DQB1* for some of the healthy controls (n = 413; mean age ± SD, 39.3 ± 11.0 years, 61 male \[14.8%\]) were used for the analyses on *DQB1* allele, *DQB1* genotype, *DRB1-DQB1* haplotype, *DRB1-DQB1* diplotype, and acid residues in the DQβ chain \[[@pone.0187325.ref024]\]. *DRB1-DQB1* haplotypes were elucidated by direct counting, because *DRB1* is in strong linkage disequilibrium with *DQB1*.

Statistical analysis {#sec009}
--------------------

Differences of AIH characteristics were analyzed by Mann-Whitney\'s U test or Fisher's exact test using 2x2 contingency tables. Association of allele carrier frequencies, haplotype carrier frequencies, or amino acid residue carrier frequencies was analyzed by Fisher's exact test using 2x2 contingency tables under the dominant model. Differences of genotype frequencies or diplotype (the specific combination of *DRB1*-*DQB1* haplotypes) frequencies were analyzed by Fisher's exact test using 2x2 contingency tables. Adjustment for multiple comparisons was conducted with Bonferroni method; corrected P (*Pc*) values were calculated by multiplying the *P* value by the number of alleles or amino acid residues tested.

Results {#sec010}
=======

Clinical features of type I AIH patients {#sec011}
----------------------------------------

Characteristics of the type I AIH patients are shown in [Table 1](#pone.0187325.t001){ref-type="table"}. Among 360 AIH patients, 314 (87.2%) were positive for ANA, 118 (38.6%) were positive for ASMA. Of overall AIH, 227 (63.1%) were definite AIH.

10.1371/journal.pone.0187325.t001

###### Characteristics of type I AIH patients.

![](pone.0187325.t001){#pone.0187325.t001g}

                                 AIH
  ------------------------------ -----------------
  Number                         360
  Male, n (%)                    43 (11.9%)
  Mean age, years (SD)           62.9 (±13.5)
  Age at onset, years (SD)       59.1 (±13.5)
  Albumin (g/dl) (SD)            3.8 (±0.6)
  Total bilirubin (mg/dl) (SD)   3.7 (±4.9)
  AST(IU/L) (SD)                 469.7 (±546.2)
  ALT(IU/L) (SD)                 507.5 (±510.1)
  ALP(IU/L) (SD)                 465.2 (±211.0)
  IgG (mg/dl) (SD)               2413.6 (±898.2)
  IgM(mg/dl) (SD)                205.9 (±228.0)
  Platelets (10^4^/μl) (SD)      18.7 (±7.1)
  ANA ≧ 1:40, n (%)              314 (87.2%)
  ASMA ≧ 1:40, n (%)             118 (38.6%)
  Cirrhosis, n (%)               49 (13.6%)
  IAIHG score (SD)               16.3 (±3.1)
  Definite AIH, n (%)            227 (63.1%)

AIH: autoimmune hepatitis, AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: Alkaline Phosphatase, IgG: immunoglobulin G, IgG: immunoglobulin M, ANA: anti-nuclear antibody, ASMA: anti-smooth muscle antibody, IAIHG: International Autoimmune Hepatitis Group. Numbers or average values of each group are shown. Percentages or standard deviations are shown in parenthesis.

*HLA-DRB1* in type I AIH {#sec012}
------------------------

To compare *HLA-DRB1* allele carrier frequency of the AIH patients and the healthy controls, we performed *HLA-DRB1* genotyping ([Table 2](#pone.0187325.t002){ref-type="table"}). A significant association between type I AIH and *DRB1\*04*:*05* (*P* = 1.89×10^−21^, corrected *P* \[*Pc*\] = 5.86×10^−20^, odds ratio \[OR\] 3.41, 95% confidence interval \[CI\] 2.65--4.38) was detected. *DRB1\*04*:*01* was also associated with type I AIH (*P* = 0.0006, *Pc* = 0.0193, OR 2.97, 95%CI 1.62--5.43). On the contrary, *DRB1\*13*:*02* was found to be protectively associated with type 1 AIH (*P* = 0.0003, *Pc* = 0.0080, OR 0.48, 95% CI 0.32--0.72). HLA-DR4 serological group was associated with type I AIH (*P* = 3.84X10^-18^, OR 2.98, 95% CI 2.32--3.83), but DR6 is protectively associated (*P* = 2.10X10^-5^, OR 0.54, 95% CI 0.41--0.72). Thus, *DRB1\*04*:*05 and DRB1\*04*:*01* were predisposing and *DRB1\*13*:*02* was protective for AIH.

10.1371/journal.pone.0187325.t002

###### *HLA-DRB1* allele carrier frequency in the AIH patients and healthy controls.
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  --------------------------------------------------------------------------------------------------------------
                         Case\        Control (n = 1026)   *P*            OR     *P*c           95%CI
                         (n = 360)                                                              
  ---------------------- ------------ -------------------- -------------- ------ -------------- ----------------
  *DRB1\*01*:*01*        26 (7.2)     110 (10.7)           0.0634         0.65   NS             (0.42--1.01)

  *DRB1\*03*:*01*        1 (0.3)      3 (0.3)              1.0000         0.95   NS             (0.10--9.16)

  *DRB1\*04*:*01*        22 (6.1)     22 (2.1)             0.0006         2.97   0.0193         (1.62--5.43)

  *DRB1\*04*:*03*        15 (4.2)     47 (4.6)             0.8823         0.91   NS             (0.50--1.64)

  *DRB1\*04*:*04*        0 (0.0)      4 (0.4)              0.5780         0.32   NS             (0.02--5.87)

  *DRB1\*04*:*05*        185 (51.4)   243 (23.7)           1.89X10^-21^   3.41   5.68X10^-20^   (2.65--4.38)

  *DRB1\*04*:*06*        15 (4.2)     76 (7.4)             0.0351         0.54   NS             (0.31--0.96)

  *DRB1\*04*:*07*        5 (1.4)      15 (1.5)             1.0000         0.95   NS             (0.34--2.63)

  *DRB1\*04*:*10*        12 (3.3)     32 (3.1)             0.8616         1.07   NS             (0.55--2.10)

  *DRB1\*07*:*01*        2 (0.6)      9 (0.9)              0.7382         0.63   NS             (0.14--2.94)

  *DRB1\*08*:*02*        35 (9.7)     72 (7.0)             0.1080         1.43   NS             (0.93--2.18)

  *DRB1\*08*:*03*        58 (16.1)    153 (14.9)           0.6091         1.10   NS             (0.79--1.52)

  *DRB1\*08*:*09*        0 (0.0)      2 (0.2)              1.0000         0.57   NS             (0.03--11.87)

  *DRB1\*09*:*01*        77 (21.4)    280 (27.3)           0.0298         0.72   0.8949         (0.54--0.97)

  *DRB1\*10*:*01*        5 (1.4)      5 (0.5)              0.1381         2.88   NS             (0.83--9.99)

  *DRB1\*11*:*01*        8 (2.2)      41 (4.0)             0.1361         0.55   NS             (0.25--1.18)

  *DRB1\*12*:*01*        25 (6.9)     75 (7.3)             0.9059         0.95   NS             (0.59--1.51)

  *DRB1\*12*:*02*        11 (3.1)     37 (3.6)             0.7384         0.84   NS             (0.43--1.67)

  *DRB1\*13*:*01*        2 (0.6)      8 (0.8)              1.0000         0.71   NS             (0.15--3.36)

  *DRB1\*13*:*02*        30 (8.3)     163 (15.9)           0.0003         0.48   0.0080         (0.32--0.72)

  *DRB1\*14*:*02*        1 (0.3)      0 (0.0)              0.2597         8.57   NS             (0.35--210.76)

  *DRB1\*14*:*03*        5 (1.4)      44 (4.3)             0.0078         0.31   0.2337         (0.12--0.80)

  *DRB1\*14*:*04*        0 (0.0)      4 (0.4)              0.5780         0.32   NS             (0.02--5.87)

  *DRB1\*14*:*05*        13 (3.6)     40 (3.9)             0.8744         0.92   NS             (0.49--1.75)

  *DRB1\*14*:*06*        5 (1.4)      29 (2.8)             0.1655         0.48   NS             (0.19--1.26)

  *DRB1\*14*:*07*        1 (0.3)      2 (0.2)              1.0000         1.43   NS             (0.13--15.78)

  *DRB1\*14*:*54*        20 (5.6)     58 (5.7)             1.0000         0.98   NS             (0.58--1.66)

  *DRB1\*15*:*01*        41 (11.4)    139 (13.5)           0.3171         0.82   NS             (0.57--1.19)

  *DRB1\*15*:*02*        62 (17.2)    224 (21.8)           0.0692         0.74   NS             (0.55--1.02)

  *DRB1\*16*:*02*        5 (1.4)      18 (1.8)             0.8119         0.79   NS             (0.29--2.14)

  DR4                    238 (66.1)   406 (39.6)           3.84X10^-18^   2.98                  (2.32--3.83)

  DR6 (*\*13*, *\*14*)   74 (20.6)    332 (32.4)           2.10X10^-5^    0.54                  (0.41--0.72)

  DR8                    92 (25.6)    220 (21.4)           0.1234         1.26                  (0.95--1.66)
  --------------------------------------------------------------------------------------------------------------

AIH: autoimmune hepatitis, OR: odds ratio, CI: confidence interval, *P*c: corrected *P* value, NS: not significant. Allele carrier frequencies are shown in parenthesis (%). Association was tested by Fisher\'s exact test using 2x2 contingency tables under the dominant model.

*Demographic features of type I AIH patients with or without* DRB1\*04:05 *or* \*13:02

Clinical features of AIH patients with or without *DRB1\*04*:*05 or \*13*:*02* were compared ([Table 3](#pone.0187325.t003){ref-type="table"}). Serum levels of Immunoglobulin G (IgG), Immunoglobulin M (IgM), and IAIHG score were higher in AIH patients with *DRB1\*04*:*05* than without. Positive rate of ASMA and the rate of definite AIH were higher in AIH patients with *DRB1\*04*:*05* than without. The complication rate of cirrhosis tended to be higher in AIH patients with *DRB1\*13*:*02* than without. Thus, specific clinical features of AIH patients possessing *DRB1\*04*:*05* were observed.

10.1371/journal.pone.0187325.t003

###### Comparison of the demographics between AIH patients with or without *DRB1\*04*:*05* or *\*13*:*02*.
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                                 *DRB1\*04*:*05*(+)   *DRB1\*04*:*05*(-)   *P*                                                 *DRB1\*13*:*02*(+)   *DRB1\*13*:*02*(-)   *P*
  ------------------------------ -------------------- -------------------- --------------------------------------------------- -------------------- -------------------- ---------------------------------------------
  Number                         185                  175                                                                      30                   330                  
  Male, n (%)                    20 (10.8%)           23 (13.1%)           [\*](#t003fn002){ref-type="table-fn"}0.5193         2 (6.7%)             41 (12.4%)           [\*](#t003fn002){ref-type="table-fn"}0.5559
  Age at onset, years (SD)       58.1 (±14.3)         59.2 (±14.7)         0.2897                                              59.5 (±15.8)         58.5 (±14.4)         0.6174
  Mean age, years (SD)           63.2 (±12.2)         62.6 (±14.8)         0.6877                                              62.0 (±15.9)         63.0 (±13.3)         0.9408
  Albumin (g/dl) (SD)            3.7 (±0.7)           3.8 (±0.9)           0.2699                                              3.7 (±0.6)           3.8 (±0.8)           0.2744
  Total bilirubin (mg/dl) (SD)   3.6 (±4.6)           3.8 (±5.2)           0.8023                                              4.4 (±5.6)           3.6 (±4.9)           0.2202
  AST(IU/L) (SD)                 428.5 (±409.7)       513.2 (±659.0)       0.5735                                              498.4 (±498.4)       467.1 (±550.9)       0.7813
  ALT(IU/L) (SD)                 488.1 (±492.3)       525.1 (±529.0)       0.7793                                              549.4 (±562.2)       502.2 (±505.8)       0.8568
  ALP(IU/L) (SD)                 450.3 (±185.0)       478.4 (±237.1)       0.6656                                              463.8 (±217.1)       464.0 (±212.0)       0.9474
  IgG (mg/dl) (SD)               2587.1 (±1005.7)     2119.8 (±840.8)      2.10X10^-6^                                         2242.9 (±878.5)      2370.6 (±964.3)      0.3771
  IgM(mg/dl) (SD)                216.5 (±283.5)       144.1 (±126.2)       0.0020                                              140.3 (±125.5)       185.0 (±230.7)       0.1716
  Platelets (104/μl) (SD)        18.5 (±7.1)          18.5 (±7.5)          0.9008                                              18.1 (±6.6)          18.5 (±7.4)          0.8625
  ANA ≧ 1:40, n (%)              164 (88.6%)          150 (85.7%)          [\*](#t003fn002){ref-type="table-fn"}0.4328         29 (96.7%)           285 (86.4%)          [\*](#t003fn002){ref-type="table-fn"}0.1510
  ASMA ≧ 1:40, n (%)             91 (55.2%)           27 (19.1%)           [\*](#t003fn002){ref-type="table-fn"}6.46X10^-11^   7 (33.3%)            111 (38.9%)          [\*](#t003fn002){ref-type="table-fn"}0.6515
  Cirrhosis, n (%)               26 (14.1%)           23 (13.1%)           [\*](#t003fn002){ref-type="table-fn"}0.8782         8 (26.7%)            41 (12.4%)           [\*](#t003fn002){ref-type="table-fn"}0.0462
  IAIHG score (SD)               16.9 (3.1%)          15.6 (2.9%)          1.54X10^-5^                                         15.7 (2.9%)          16.3 (3.1%)          0.3476
  Definite AIH, n (%)            133 (71.9%)          94 (53.7%)           [\*](#t003fn002){ref-type="table-fn"}0.0005         17 (56.7%)           210 (63.6%)          [\*](#t003fn002){ref-type="table-fn"}0.4383

Association was tested between AIH patients with or without *DRB1\*04*:*05* or *\*13*:*02* by Fisher\'s exact test using 2x2 contingency tables or Mann-Whitney\'s U test.

\*Fisher\'s exact test was employed.

*HLA-DRB1* genotype in type I AIH {#sec013}
---------------------------------

We investigated the genotype frequency in the AIH patients ([Table 4](#pone.0187325.t004){ref-type="table"}). The homozygosity for *DRB1\*04*:*05* (OR 2.79, 95% CI 1.45--5.38) did not confer higher OR for AIH than heterozygosity for *DRB1\*04*:*05* (OR 3.10, 95% CI 2.40--4.00). In contrast, the homozygosity for *DRB1\*13*:*02* (OR 0.15, 95% CI 0.01--2.56) conferred lower OR than heterozygosity for *DRB1\*13*:*02* (OR 0.51, 95% CI 0.34--0.78). The frequency of the *DRB1\*04*:*05/\*13*:*02* genotype was comparable. Of interest, higher frequencies of *DRB1\*04*:*05/\*08*:*02* (*P* = 3.78X10^-6^, OR 6.70, 95% CI 2.89--15.54) and *DRB1\*04*:*05/\*08*:*03* (*P* = 9.80X10^-7^, OR 4.54, 95% CI 2.47--8.35) genotypes in AIH were observed. Similarly, the DR4/DR8 genotype frequency in AIH was markedly increased (*P* = 3.12×10^−9^, OR 3.52, 95% CI 2.34--5.29). Thus, some specific heterozygous genotypes were predisposing for AIH.

10.1371/journal.pone.0187325.t004

###### *HLA-DRB1* genotype frequency in the AIH patients and controls.
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                                Case (n = 360)   Control (n = 1026)   *P*            OR      95%CI
  ----------------------------- ---------------- -------------------- -------------- ------- ----------------
  *\*04*:*05*/not *\*04*:*05*   167 (46.4)       224 (21.8)           5.72X10^-18^   3.10    (2.40--4.00)
  *\*13*:*02*/not *\*13*:*02*   30 (8.3)         154 (15.0)           0.0011         0.51    (0.34--0.78)
  *\*04*:*01*/not *\*04*:*01*   22 (6.1)         21 (2.0)             0.0003         3.11    (1.69--5.74)
  *\*04*:*01*/*\*04*:*05*       4 (1.1)          1 (0.1)              0.0178         11.52   (1.28--103.39)
  *\*04*:*05*/*\*04*:*05*       18 (5.0)         19 (1.9)             0.0035         2.79    (1.45--5.38)
  *\*04*:*05*/*\*08*:*02*       18 (5.0)         8 (0.8)              3.78X10^-6^    6.70    (2.89--15.54)
  *\*04*:*05*/*\*08*:*03*       27 (7.5)         18 (1.8)             9.80X10^-7^    4.54    (2.47--8.35)
  *\*04*:*05*/*\*13*:*02*       8 (2.2)          25 (2.4)             1.0000         0.91    (0.41--2.04)
  *\*13*:*02*/*\*13*:*02*       0 (0.0)          9 (0.9)              0.1225         0.15    (0.01--2.56)
  DR4/DR4                       34 (9.4)         57 (5.6)             0.0132         1.77    (1.14--2.76)
  DR8/DR8                       5 (1.4)          16 (1.6)             1.0000         0.89    (0.32--2.44)
  DR6/DR6                       3 (0.8)          25 (2.4)             0.0796         0.34    (0.10--1.12)
  DR4/DR8                       54 (15.0)        49 (4.8)             3.12X10^-9^    3.52    (2.34--5.29)
  DR4/DR6                       32 (8.9)         90 (8.8)             0.9144         1.01    (0.66--1.55)

AIH: autoimmune hepatitis, OR: odds ratio, 95%CI: confidence interval. Genotype frequencies are shown in parenthesis (%). Association was tested by Fisher\'s exact test using 2X2 contingency tables.

Certain amino acid residues in HLA-DRβ chains were associated with AIH {#sec014}
----------------------------------------------------------------------

The association with AIH with respect to each amino acid residue in the HLA-DRβ chain was analyzed. The amino acid residues of 11V, 13H, 33H, 57S, and 96Y in the DRβ chain showed associations with AIH ([Fig 1](#pone.0187325.g001){ref-type="fig"}). Thus, this association analysis suggested roles for specific amino acid residues in the HLA-DRβ chain.

![Associations of amino acid residues in DRβ chain with AIH.\
Each amino acid residue frequency in the HLA-DRβ chain for the 1026 healthy controls was compared with that of the AIH patients. Differences of amino acid residue carrier frequencies were analyzed by Fisher's exact test using 2x2 contingency tables. Corrected *P* (*P*c) values were calculated by multiplying the *P* value by the number of amino acid residues tested. Predisposing associations were indicated by filled circles and protective associations by open circles.](pone.0187325.g001){#pone.0187325.g001}

*HLA-DQB1* in type I AIH {#sec015}
------------------------

We next tried to compare *HLA-DQB1* allele carrier frequency of the AIH patients with 413 of the 1026 healthy controls, since previously reported genotyping results of *DQB1* were available for the 413 healthy controls\[[@pone.0187325.ref024]\]. When *DRB1* genotyping results for the 413 healthy controls were compared with those of the AIH patients, similar tendencies were observed ([S1](#pone.0187325.s002){ref-type="supplementary-material"} and [S2](#pone.0187325.s003){ref-type="supplementary-material"} Tables). *DQB1\*04*:*01* allele was strongly associated with AIH (*P* = 4.66×10^−18^, *Pc* = 6.99×10^−17^, OR 3.89, 95% CI 2.84--5.33, [S3 Table](#pone.0187325.s004){ref-type="supplementary-material"}). We further examined *HLA-DQB1* genotype ([S4 Table](#pone.0187325.s005){ref-type="supplementary-material"}). The homozygosity for *DQB1\*04*:*01* (OR 4.04, 95% CI 1.48--11.08) conferred comparative OR compared with heterozygosity for *DQB1\*04*:*01* (OR 3.47, 95% CI 2.52--4.77). The higher frequency of *DQB1\*04*:*01/\*06*:*01* genotype in AIH was observed (*P* = 8.75X10^-6^, OR 3.24, 95% CI 1.89--5.56). Thus, some of *DQB1*alleles or genotypes were predisposing for AIH.

*DRB1-DQB1* haplotype in type I AIH {#sec016}
-----------------------------------

*DRB1-DQB1* haplotype carrier frequencies were compared between the AIH patients and the 413 healthy controls ([Table 5](#pone.0187325.t005){ref-type="table"}). Higher carrier frequencies of *DRB1\*04*:*01-DQB1\*03*:*01* (*P* = 0.0007, OR 4.42 95% CI 1.77--11.01) and *DRB1\*04*:*05-DQB1\*04*:*01* (*P* = 1.99×10^−20^, OR 4.32, 95% CI 3.14--5.96) were found in the AIH patients. *DRB1-DQB1* diplotype frequencies were also compared between the AIH patients and the 413 healthy controls ([Table 5](#pone.0187325.t005){ref-type="table"}). The homozygosity for *DRB1\*04*:*05-DQB1\*04*:*01* (OR 5.07, 95% CI 1.69--15.20) conferred slightly higher OR for AIH than heterozygosity for *DRB1\*04*:*05-DQB1\*04*:*01* (OR 3.81, 95% CI 2.76--5.28). The diplotype frequencies of *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*02-DQB1\*03*:*02* (*P* = 0.0004, OR 24.77, 95% CI 1.45--424.31) and *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*03-DQB1\*06*:*01* (*P* = 1.18×10^−6^, OR 10.64, 95% CI 3.19--35.46) were higher in AIH patients, suggesting the predisposing role of some specific heterozygous diplotypes in AIH.

10.1371/journal.pone.0187325.t005

###### *DRB1-DQB1* haplotype carrier or diplotype frequency in the AIH patients and controls.

![](pone.0187325.t005){#pone.0187325.t005g}

  --------------------------------------------------------------------------------------------------------------
  *DRB1-DQB*1 haplotype                         Case\        Control\    *P*            OR      95%CI
                                                (n = 360)    (n = 413)                          
  --------------------------------------------- ------------ ----------- -------------- ------- ----------------
  *\*04*:*01-\*03*:*01*                         22 (6.1)     6 (1.5)     0.0007         4.42    (1.77--11.01)

  *\*04*:*05-\*04*:*01*                         182 (50.6)   79 (19.1)   1.99X10^-20^   4.32    (3.14--5.96)

  *\*08*:*02-\*03*:*02*                         21 (5.8)     21 (5.1)    0.7508         1.16    (0.62--2.15)

  *\*08*:*02-\*04*:*02*                         13 (3.6)     16 (3.9)    1.0000         0.93    (0.44--1.96)

  *\*08*:*03-\*03*:*01*                         3 (0.8)      2 (0.5)     0.6682         1.73    (0.29--10.39)

  *\*08*:*03-\*06*:*01*                         57 (15.8)    57 (13.8)   0.4768         1.17    (0.79--1.75)

  *\*13*:*02-\*06*:*04*                         31 (8.6)     49 (11.9)   0.1559         0.70    (0.44--1.12)

  *DRB1-DQB1* diplotype                                                                         

  *\*0405-\*0401*/not *\*04*:*05-\*04*:*01*     165 (45.8)   75 (18.2)   1.17X10^-16^   3.81    (2.76--5.28)

  *\*04*:*05-\*04*:*01*/*\*04*:*01-\*03*:*01*   4 (1.1)      1 (0.2)     0.1898         4.63    (0.52--41.61)

  *\*04*:*05-\*04*:*01*/*\*04*:*05-\*04*:*01*   17 (4.7)     4 (1.0)     0.0015         5.07    (1.69--15.20)

  *\*04*:*05-\*04*:*01*/*\*08*:*02-\*03*:*02*   10 (2.8)     0 (0.0)     0.0004         24.77   (1.45--424.31)

  *\*04*:*05-\*04*:*01*/*\*08*:*02-\*04*:*02*   7 (1.9)      3 (0.7)     0.2017         2.71    (0.70--10.56)

  *\*04*:*05-\*04*:*01*/*\*08*:*03-\*03*:*01*   1 (0.3)      0 (0.0)     0.4657         3.45    (0.14--84.97)

  *\*04*:*05-\*04*:*01*/*\*08*:*03-\*06*:*01*   26 (7.2)     3 (0.7)     1.18X10^-6^    10.64   (3.19--35.46)

  *\*04*:*05-\*04*:*01*/*\*13*:*02-\*06*:*04*   8 (2.2)      8 (1.9)     0.8052         1.15    (0.43--3.10)
  --------------------------------------------------------------------------------------------------------------

AIH: autoimmune hepatitis, OR: odds ratio, 95%CI: confidence interval. Genotype frequencies are shown in parenthesis (%). Association was tested by Fisher\'s exact test using 2X2 contingency tables.

Certain amino acid residues in HLA-DQβ chains were associated with AIH {#sec017}
----------------------------------------------------------------------

The association with AIH with respect to each amino acid residue in the HLA-DQβ chain was analyzed in the comparison with the 413 healthy controls. The amino acid residues of 23L, 56L, 70E, and 71D in the DQβ chain showed associations with AIH ([Fig 2](#pone.0187325.g002){ref-type="fig"}). When each amino acid residue frequency in the DRβ chain for the 413 healthy controls was compared with that of the AIH patients, similar tendencies were observed ([S1 Fig](#pone.0187325.s001){ref-type="supplementary-material"}). Thus, this association analysis suggested roles for specific amino acid residues in the HLA-DQβ chains.

![Associations of amino acid residues in DQβ chain with AIH.\
Each amino acid residue frequency in the HLA-DRβ chain for the 413 healthy controls was compared with that of the AIH patients. Differences of amino acid residue carrier frequencies were analyzed by Fisher's exact test using 2x2 contingency tables. Corrected *P* (*P*c) values were calculated by multiplying the *P* value by the number of amino acid residues tested. Predisposing associations were indicated by filled circles and protective associations by open circles.](pone.0187325.g002){#pone.0187325.g002}

Discussion {#sec018}
==========

Several studies have reported that type 1 AIH is associated with *HLA-DRB1\*03*:*01* and *DRB1\*04*:*01* in European \[[@pone.0187325.ref005]\] and *DRB1\*04*:*05* in Japanese populations ([Fig 3](#pone.0187325.g003){ref-type="fig"}) \[[@pone.0187325.ref006],[@pone.0187325.ref007],[@pone.0187325.ref008]\]. In the present study, we showed an association of Japanese AIH with *DRB1\*04*:*01* and *\*04*:*05*, indicating the common predisposing *DRB1\*04*:*01* allele for AIH between European and Japanese populations. *DRB1\*04*:*05* is also common predisposing allele for AIH between Latin America \[[@pone.0187325.ref013]\] and Japan. In previous studies, *DRB1\*13*:*02* was protectively associated with type 1 AIH in Latin America \[[@pone.0187325.ref011],[@pone.0187325.ref013],[@pone.0187325.ref017]\]. We also confirmed a protective association of *DRB1\*13*:*02* with Japanese AIH \[[@pone.0187325.ref008]\], but could not replicate the protective effects of *DRB1\*15*:*01* \[[@pone.0187325.ref005],[@pone.0187325.ref006]\]. These data indicated that the common protective *DRB1\*13*:*02* allele for AIH between Latin America and Japan is also the protective allele shared by multiple autoimmune diseases \[[@pone.0187325.ref019]\].

![Summary of the *HLA-DRB1* alleles associated with type 1 AIH.\
The *HLA-DRB1* alleles associated with type 1 AIH in European, Japanese, and Hispanic populations are illustrated. The underlined alleles are protective alleles.](pone.0187325.g003){#pone.0187325.g003}

Specific demographic features of Japanese AIH patients with *DRB1\*04*:*05* were observed ([Table 3](#pone.0187325.t003){ref-type="table"}). Elevated serum levels of IgG and IgM were detected in AIH patients with *DRB1\*04*:*05*, as it was previously described \[[@pone.0187325.ref007]\]. In the present study, the IAIHG score, the positive rate of ASMA, and the rate of definite AIH were newly found to be higher in Japanese AIH patients with *DRB1\*04*:*05*. Although *HLA* alleles are known to confer the risk for various autoimmune diseases, the precise mechanisms have not sufficiently been revealed. Thus, Japanese AIH patients with *DRB1\*04*:*05* have typical clinical traits, probably because the auto-antigens presented by DRB1\*04:05 molecules would be important for development of the typical clinical traits of AIH.

It is well known that *DRB1\*04*:*01* in European \[[@pone.0187325.ref026],[@pone.0187325.ref027]\] and *DRB1\*04*:*05* in Japanese populations \[[@pone.0187325.ref023],[@pone.0187325.ref028]\] are associated with the susceptibility for rheumatoid arthritis (RA) and type 1 diabetes, in an analogous fashion to AIH. RA is a systemic autoimmune disease that affects synovial joints. RA-susceptible *DRB1* alleles shared a conserved amino acid sequence at position 70--74 (QKRAA, RRRAA, or QRRAA) in HLA-DRβ chain and were designated as shared epitope alleles \[[@pone.0187325.ref023],[@pone.0187325.ref026]\]. The shared epitope alleles include *DRB1\*01*:*01*, *\*04*:*01*, *\*04*:*04*, *\*04*:*05*, *\*04*:*10*, *\*10*:*01*, *\*14*:*02*, and *\*14*:*06*. However, neither *DRB1\*01*:*01* nor *\*04*:*10* seems to be a risk allele for AIH ([Table 2](#pone.0187325.t002){ref-type="table"}). In the associations of *DRB1* alleles with susceptibility to RA, a gene dosage effect was reported; homozygosity for predisposing *DRB1* alleles confers higher OR than heterozygosity. However, we could not find any gene dosage effects of predisposing alleles or haplotypes in AIH. These data suggested the differential roles of *DRB1* in the pathogenesis between AIH and RA.

Type 1 diabetes is an autoimmune disease that affects pancreatic β cells producing insulin, resulting in the dysregulation of glucose metabolism. Susceptible *DRB1* alleles for type 1 diabetes are *DRB1\*03*:*01*, *\*04*:*01*, *\*04*:*02*, *\*04*:*04*, *\*04*:*05*, and *\*08*:*01* and protective alleles are *DRB1\*15*:*01*, *\*14*:*01*, and *\*07*:*01* in European populations \[[@pone.0187325.ref027]\]. In Japanese populations, *DRB1\*04*:*05*, *\*08*:*02*, and *\*09*:*01* are predisposing alleles for type 1 diabetes and *DRB1\*15*:*02* is a protective allele \[[@pone.0187325.ref028]\]. No gene dosage effect was observed for *DRB1\*04*:*05*, though a gene dosage effect for *DRB1\*09*:*01* was detected for type 1 diabetes. Similarly, we did not detect any gene dosage effects of the predisposing *DRB1\*04*:*05* allele in AIH ([Table 4](#pone.0187325.t004){ref-type="table"}). In addition, higher frequencies of the DR3/DR4, DR4/DR4, and DR4/DR8 genotypes in type 1 diabetes were reported \[[@pone.0187325.ref027]\]. In an analogous fashion, frequencies of the DR4/DR8 genotypes were higher in Japanese type 1 AIH ([Table 4](#pone.0187325.t004){ref-type="table"}). Since the allele frequency of DR4 is higher than that of DR8 in Japanese populations, DR4 is a risk allele by itself, but DR8 is not, and type 1 AIH is a multifactorial disease, the DR4/DR8 genotype could not mainly contribute to the pathogenesis of type 1 AIH. It was also reported that the association of *DRB1\*08* with the susceptibility of type 1 AIH was not detected in European populations \[[@pone.0187325.ref029]\], because of low frequency of *DRB1\*08*. The DR4/DR8 heterozygous genotypes may cause an increased probability of self-antigen presentation, resulting in the increased risk of the diseases. Thus, the manner of *DRB1* association in type 1 AIH appears to be similar to that in type 1 diabetes.

Augmented frequencies of the DR3/DR4 and DR4/DR8 heterozygous genotypes in type 1 diabetes was explained by the pathologic importance of *trans*-complementing DQα-β heterodimer molecules encoded by the *DQA1* allele of one haplotype and the *DQB1* allele of the other haplotype. The low stability of these molecules in *trans* was proposed to be causative to type 1 diabetes \[[@pone.0187325.ref027],[@pone.0187325.ref030]\]. Analogously, DR4/DR8 heterozygous genotype was increased in Japanese type 1 AIH ([Table 4](#pone.0187325.t004){ref-type="table"}), suggesting that *trans*-complementing DQα-β heterodimer molecules might also play a role in AIH. *DRB1-DQB1* diplotype analysis revealed that *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*02-DQB1\*03*:*02* and *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*03-DQB1\*06*:*01* were significantly associated with AIH ([Table 5](#pone.0187325.t005){ref-type="table"}). Japanese type 1 AIH was not significantly associated with *DRB1\*08*:*02* or *\*08*:*03* ([Table 2](#pone.0187325.t002){ref-type="table"}). Neither *DQB1\*03*:*02* nor *\*06*:*01* was associated with type 1 AIH ([S1 Table](#pone.0187325.s002){ref-type="supplementary-material"}). Based on the conserved haplotype structure in the Japanese population, the *DQA1* allele in the haplotype of *DRB1\*04*:*05-DQB1\*04*:*01* is presumed to be *DQA1\*03*:*03* \[31\] and the *DQA1* alleles in *DRB1\*08*:*02-DQB1\*03*:*02* and *DRB1\*08*:*03-DQB1\*06*:*01* are estimated to be *DQA1\*03*:*01* and *\*01*:*03*, respectively. The high risk diplotype *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*02-DQB1\*03*:*02* is considered to encode DQA1\*03:03-DQB1\*04:01 and DQA1\*03:01-DQB1\*03:02 molecules in *cis* (DQα-β heterodimer molecules formed by the protein products of *DQA1* and the *DQB1* alleles from the same chromosome) and DQA1\*03:03-DQB1\*03:02 and DQA1\*03:01-DQB1\*04:01 molecules in *trans* (DQα-β heterodimer molecules formed by the protein products of *DQA1* and the *DQB1* alleles from the opposite chromosomes). The stabilities of these four types of DQα-β heterodimer molecules were estimated to be low, according to the previous study \[[@pone.0187325.ref030]\]. The other high risk diplotype *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*03-DQB1\*06*:*01* is thought to encode DQA1\*03:03-DQB1\*04:01 and DQA1\*01:03-DQB1\*06:01 molecules in *cis* and DQA1\*03:03-DQB1\*06:01 and DQA1\*01:03-DQB1\*04:01 molecules in *trans*. The stabilities of these molecules except DQA1\*01:03-DQB1\*06:01 in *cis* were also estimated to be low \[[@pone.0187325.ref030]\]. In patients with the risk diplotype *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*03-DQB1\*06*:*01*, the low stability of *trans*-complementing DQα-β heterodimer molecules could explain the pathogenesis of type 1 AIH. In the case of type 1 diabetes, each of *DRB1*, *DQA1*, and *DQB1* is believed to have independent genetic contribution in the disease susceptibility based on the data from haplotype analysis \[[@pone.0187325.ref027]\]. Similar scenario might also apply to AIH. However, such analysis could not be performed in this study, because of the limited variety of *DRB1*-*DQB1* haplotypes in Japanese populations ([Table 5](#pone.0187325.t005){ref-type="table"}). Furthermore, other culprit genes in linkage disequilibrium with *DRB1-DQB1* loci might be causative for AIH. Thus, the results of the association analyses of *DRB1* and *DQB1* in type 1 AIH could propose several lines of explanations on the mechanisms underlined in the pathogenesis.

We detected that amino acid residues of 11V, 13H, 33H, 57S, and 96Y in the HLA-DRβ chain were associated with AIH ([Fig 1A](#pone.0187325.g001){ref-type="fig"}); these amino acids were encoded by *DRB1\*04*:*05* allele. It was also found that some amino acid residues of the DQβ chains were associated with type 1 AIH ([Fig 1B](#pone.0187325.g001){ref-type="fig"}). These amino acid residues were also encoded by *DQB1\*04*:*01*. These data were influenced by the strongest predisposing haplotype *DRB1\*04*:*05-DQB1\*04*:*01* for AIH, confirming the dominance of the *DRB1\*04*:*05-DQB1\*04*:*01* haplotype in type 1 AIH in Japanese populations.

In conclusion, we showed the predisposing association of *DRB1\*04*:*01*, *DRB1\*04*:*05*, and *DQB1\*04*:*01* and the protective association of *DRB1\*13*:*02* with Japanese type 1 AIH. The association of DR4/DR8 heterozygous genotype with AIH was newly noted. With respect to *DRB1-DQB1* haplotypes, *DRB1\*04*:*01-DQB1\*03*:*01* and *DRB1\*04*:*05-DQB1\*04*:*01* haplotypes were found to be associated with type 1 AIH. Of interest, the association of *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*02-DQB1\*03*:*02* and *DRB1\*04*:*05-DQB1\*04*:*01/DRB1\*08*:*03-DQB1\*06*:*01* diplotypes was revealed. These data suggested the roles of specific combinations of *DRB1* and *DQB1* alleles or haplotypes in the pathogenesis of type 1 AIH. Further large scale studies should be performed to confirm these findings. In addition, because the *HLA* allele distribution pattern is different in other ethnic populations, it would be intriguing and informative to analyze *DRB1* and *DQB1* alleles in type 1 AIH in other populations.
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